- Home
- MYNZ vs BIAF Comparison
MYNZ vs BIAF Comparison
Compare MYNZ & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- BIAF
- Stock Information
- Founded
- MYNZ 2021
- BIAF 2014
- Country
- MYNZ Germany
- BIAF United States
- Employees
- MYNZ N/A
- BIAF N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MYNZ Health Care
- BIAF Health Care
- Exchange
- MYNZ Nasdaq
- BIAF Nasdaq
- Market Cap
- MYNZ 7.9M
- BIAF 7.6M
- IPO Year
- MYNZ 2021
- BIAF 2022
- Fundamental
- Price
- MYNZ $1.49
- BIAF $2.94
- Analyst Decision
- MYNZ Buy
- BIAF Hold
- Analyst Count
- MYNZ 2
- BIAF 1
- Target Price
- MYNZ $14.00
- BIAF N/A
- AVG Volume (30 Days)
- MYNZ 499.8K
- BIAF 8.4M
- Earning Date
- MYNZ 09-26-2025
- BIAF 11-13-2025
- Dividend Yield
- MYNZ N/A
- BIAF N/A
- EPS Growth
- MYNZ N/A
- BIAF N/A
- EPS
- MYNZ N/A
- BIAF N/A
- Revenue
- MYNZ $659,935.00
- BIAF $7,681,059.00
- Revenue This Year
- MYNZ $26.06
- BIAF N/A
- Revenue Next Year
- MYNZ $4.97
- BIAF $20.04
- P/E Ratio
- MYNZ N/A
- BIAF N/A
- Revenue Growth
- MYNZ N/A
- BIAF 4.99
- 52 Week Low
- MYNZ $1.28
- BIAF $2.34
- 52 Week High
- MYNZ $14.39
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- MYNZ 43.48
- BIAF 50.20
- Support Level
- MYNZ $1.28
- BIAF $2.55
- Resistance Level
- MYNZ $1.73
- BIAF $3.50
- Average True Range (ATR)
- MYNZ 0.14
- BIAF 0.35
- MACD
- MYNZ -0.01
- BIAF -0.12
- Stochastic Oscillator
- MYNZ 44.67
- BIAF 44.96
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.